CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity

Journal of Negative Results in BioMedicine

Volumn 3, Issue , 2004, Pages

  Tanner, Stefan ^a   Barberis, Alcide ^a  

^a ESBATech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; PROTEIN P53;

ARTICLE; CANCER CELL; DRUG ACTIVITY; DRUG DNA INTERACTION; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MAMMAL CELL; NONHUMAN; OSTEOBLAST; YEAST;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; DAUNORUBICIN; GENES, REPORTER; HUMANS; PYRIMIDINES; SACCHAROMYCES CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12244260150     PISSN: 14775751     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-5751-3-5     Document Type: Article

References (28)

1. Ko LJ, Prives C: p53: puzzle and paradigm. Genes & Dev 1996, 10:1054-72.
2. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network [news] [In Process Citation]. Nature 2000, 408:307-10.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53.
4. Hupp TR, Sparks A, Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83:237-45.
5. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997, 3:632-8.
6. Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L: Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 1999, 18:551-7.
7. Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function [see comments]. Science 1999, 286:2507-10.
8. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR: A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A 2002, 99:937-942.
9. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low- molecularweight compound. Nat Med 2002, 8:282-8.
10. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR: Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002, 21:2119-29.
11. Scharer E, Iggo R: Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 1992, 20:1539-45.
12. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-25.
13. Bullock AN, Henckel J, Fersht AR: Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000, 19:1245-56.
14. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG: Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999, 19:3395-402.
15. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-36.
16. Kaeser MD, Iggo RD: From the Cover: Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity invivo. Proc Natl Acad Sci U S A 2002, 99:95-100.
17. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-41.
18. Hupp TR, Lane DP: Allosteric activation of latent p53 tetramers. Curr Biol 1994, 4:865-75.
19. Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE, Arrowsmith CH: Latent and active p53 are identical in conformation. Nat Struct Biol 2001, 8:756-60.
20. Espinosa JM, Emerson BM: Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001, 8:57-69.
21. Wang W, Takimoto R, Rastinejad F, El-Deiry WS: Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003, 23:2171-81.
22. Luu Y, Bush J, Cheung KJ Jr, Li G: The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/ mitochondrial/caspase-9 pathway. Exp Cell Res 2002, 276:214-22.
23. Barberis A, Pearlberg J, Simkovich N, Farrell S, Reinagel P, Bamdad C, Sigal G, Ptashne M: Contact with a component of the polymerase II holoenzyme suffices for gene activation. Cell 1995, 81:359-68.
24. Kaiser C, Michaelis S, Mitchell A: Methods in yeast genetics New York: Cold Spring Harbor Laboratory Press; 1994.
25. Gietz RD, Schiestl RH, Willems AR, Woods RA: Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/ PEG procedure. Yeast 1995, 11:355-60.
26. Auf der Maur A, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C, Escher D, Pluckthun A, Barberis A: Direct in vivo screening of intrabody libraries constructed on a highly stable singlechain framework. J Biol Chem 2002, 277:45075-85.
27. Enslen H, Myung PS, Maurer RA, Sun P: Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes & Dev 1994, 8:2527-39.
28. Sadowski I, Ma J, Triezenberg S, Ptashne M: GAL4-VP16 is an unusually potent transcriptional activator. Nature 1988, 335:563-4.